See every side of every news story

Published 5 days ago • loading... • Updated 5 days ago

Millions in funding for the development of a novel drug against multi-resistant bacteria

Summary by bionity.com

The Justus Liebig University Giessen (JLU) and the company Infex Therapeutics, a biotech company specializing in drugs against infectious diseases, are receiving over one million euros in funding for the development of a new drug against multi-resistant bacteria. As part of the funding...

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

1 Articles

All

Left

Center

Right

Millions in funding for the development of a novel drug against multi-resistant bacteria

The Justus Liebig University Giessen (JLU) and the company Infex Therapeutics, a biotech company specializing in drugs against infectious diseases, are receiving over one million euros in funding for the development of a new drug against multi-resistant bacteria. As part of the funding...

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources1

Leaning Left0Leaning Right0Center0Last Updated5 days agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

bionity.com broke the news in 5 days ago on Tuesday, February 18, 2025.

Sources are mostly out of (0)

Similar News Topics

Stories disproportionately reported by the Left or the Right

Similar News Topics